Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Several cytotoxic anticancer drugs inhibit DNA replication and/or mitosis, while EGFR tyrosine kinase inhibitors inactivate EGFR signalling in cancer cell. Both types of anticancer drugs improve the overall survival of the patients with non-small-cell lung cancer (NSCLC), although tumors often become refractory to this treatment. Despite several mechanisms by which the tumors become resistant having been described the effect of these compounds on anti-tumor immunity remains largely unknown. METHODS: This study examines the effect of the cytotoxic drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on the expression of NK group 2 member D (NKG2D) ligands as well as the sensitivity of NSCLC cells to the NK-mediated lysis. RESULTS: We demonstrate that Gemcitabine treatment leads to an enhanced expression, while Gefitinib downregulated the expression of molecules that act as key ligands for the activating receptor NKG2D and promote NK cell-mediated recognition and cytolysis. Gemcitabine activated ATM and ATM- and Rad-3-related protein kinase (ATR) pathways. The Gemcitabine-induced phosphorylation of ATM as well as the upregulation of the NKG2D ligand expression could be blocked by an ATM-ATR inhibitor. In contrast, Gefitinib attenuated NKG2D ligand expression. Silencing EGFR using siRNA or addition of the PI3K inhibitor resulted in downregulation of NKG2D ligands. The observations suggest that the EGFR/PI3K pathway also regulates the expression of NKG2D ligands. Additionally, we showed that both ATM-ATR and EGFR regulate MICA/B via miR20a. CONCLUSION: In keeping with the effect on NKG2D expression, Gemcitabine enhanced NK cell-mediated cytotoxicity while Gefitinib attenuated NK cell killing in NSCLC cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“potentially reflecting a cell-type-dependent mechanism linked to EGFR mutational status and/or the concentration of the drug employed in this context”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Okita et al., 2015
Experimental — accuracy not yet measuredIn the citing paper
“NKAL downregulation in NSCLC cells, linked to reduced NK-mediated ADCC”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Okita et al., 2015
In the citing paper
“similar findings have not been reproduced by independent investigators”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Okita et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“Since the PI3K/AKT and the RAS/MAPK pathways are the major downstream pathways of EGFR signaling [38], we evaluated whether these pathways regulate the expression of NKG2D ligands in the NSCLC cells.”
BackgroundReal-time quantification of microRNAs by stem-loop RT-PCR
Chen, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni178 · Cited by 4,952 · cited 1×
“Real-time quantification of miRNAs was assayed as previously described [29].”
MethodMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · cited 2×
“Additionally, EGFR tyrosine kinase inhibitors (EGFR-TKI) have increased the median survival time of advanced patients with EGFR-mutated NSCLC to>24 months [3].”
BackgroundVlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240 · cited 4×
“PC–9 cells were treated with the PI3K inhibitor LY294002 [39] or the MEK inhibitor PD98059 [40].”
BackgroundInfluentialActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999 · cited 12×
“Gemcitabine upregulated the expression of MHC class I molecules, MICA, and ULBP–2/5/6 in A549 cells (Fig 2A and 2B), and the expression of MICA, MICB, and ULBP–2/5/6 in RERFLC-AI cells (S2A Fig).”
BackgroundInfluentialSelective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161 · cited 1×
“In contrast, NK cell activity could be inhibited by the interaction of the killer-cell immunoglobulin-like receptor (KIR) on NK cells with the major histocompatibility complex (MHC) class I molecules thereby preventing cytotoxicity against normal self [8, 9].”
BackgroundSelf-citationThe DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308 · cited 5×
“It is reported that the expression of NKG2D ligands is regulated by DNA stress-induced ATM-ATR signaling [15], while other groups including us reported that oncogenes BCL/ABL and HER3 also regulated the expression of NKG2D ligands in transformed cells via mainly PI3K-AKT pathway [16, 17].”
BackgroundResultInfluentialCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“An important NKG2D ligand is the MHC class I chain A and B (MICA and MICB) [5] and UL16-binding proteins (ULBPs) [10], which are expressed at low levels on the non-malignant cell types while primary tumor cells and tumor cell lines frequently express NKG2D ligands [11].”
BackgroundHickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220 · cited 8×
“To determine whether ATM-ATR pathways regulate the NKG2D ligand expression in NSCLC, A549 cells were treated with the ATM-ATR inhibitors Caffeine [31, 32] or KU55933 [33].”
MethodInfluentialAn Activating Immunoreceptor Complex Formed by NKG2D and DAP10
Wu, J., Song, Y., Bakker, A. B. H., Bauer, S., Spies, T., Lanier, L. L., & Phillips, J. H. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,039
(1999) · PubMed · Cited by 1,030
Groh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017 · cited 2×
“An important NKG2D ligand is the MHC class I chain A and B (MICA and MICB) [5] and UL16-binding proteins (ULBPs) [10], which are expressed at low levels on the non-malignant cell types while primary tumor cells and tumor cell lines frequently express NKG2D ligands [11].”
BackgroundBindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Pang, L., Sawada, T., Decker, S. J., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.23.13585 · Cited by 896 · cited 4×
“PC–9 cells were treated with the PI3K inhibitor LY294002 [39] or the MEK inhibitor PD98059 [40].”
BackgroundInfluentialRanson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763 · cited 1×
“pharmacokinetic analysis showed the serum concentration of Gefitinib reached less than 1 μM in the clinical setting [36].”
BackgroundEvaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., & Grindey, G. B. (1990) · PubMed · Cited by 680
Activation, coactivation, and costimulation of resting human natural killer cells
Bryceson, Y. T., March, M. E., Ljunggren, H., & Long, E. O. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00457.x · Cited by 650 · cited 1×
“In addition, tumor cells expressing NKG2D ligand can become susceptible to NK cell killing even in the presence of normal MHC class I expression [5, 13].”
BackgroundCerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606 · cited 1×
“Thus, the balance between NKG2D ligands and MHC class I expression on transformed cells is important for their survival during immune surveillance of their host [14].”
BackgroundProspects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543 · cited 2×
“NKG2D ligands induced by chemotherapeutic reagents such as Gemcitabine could represent one important mechanism, which the tumor cells are eradicated by the innate immune system [12].”
BackgroundSoriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460 · cited 7×
“To determine whether ATM-ATR pathways regulate the NKG2D ligand expression in NSCLC, A549 cells were treated with the ATM-ATR inhibitors Caffeine [31, 32] or KU55933 [33].”
MethodInfluentialNatural Killer Cell Education and Tolerance
Orr, M. T., & Lanier, L. L. (2010) · Cell · doi:10.1016/j.cell.2010.08.031 · Cited by 441
Moretta, A., Bottino, C., Pende, D., Tripodi, G., Tambussi, G., Viale, O., Orengo, A., Barbaresi, M., Merli, A., & Ciccone, E. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.6.1589 · Cited by 385 · cited 1×
“In contrast, NK cell activity could be inhibited by the interaction of the killer-cell immunoglobulin-like receptor (KIR) on NK cells with the major histocompatibility complex (MHC) class I molecules thereby preventing cytotoxicity against normal self [8, 9].”
BackgroundHuman microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Stern-Ginossar, N., Gur, C., Biton, M., Horwitz, E., Elboim, M., Stanietsky, N., Mandelboim, M., & Mandelboim, O. (2008) · Nature Immunology · doi:10.1038/ni.1642 · Cited by 315 · cited 2×
“It has been previously reported that several miRNA suppress the expression of NKG2D ligands [20, 42].”
BackgroundVenkataraman, G. M., Suciu, D., Groh, V., Boss, J. M., & Spies, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.961 · Cited by 191 · cited 1×
“It has been demonstrated that NKG2D ligand expression can be induced by activation of the DNA stress sensing ATM-ATR [15] or the NKG2D ligand gene transcription via oxidative stress [30].”
BackgroundHeinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187 · cited 1×
“Cytotoxic anticancer drugs inhibit DNA replication [23] or mitosis [24, 25] resulting in apoptosis in several types of cancers including NSCLC [26], while EGFR-TKI inactivates EGFR signalling in NSCLC cells [27].”
BackgroundEpidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169 · cited 2×
“In line with a previous report [37], Gefitinib upregulated the expression of MHC class I antigens in both PC–9 and A549 cells.”
ResultTolis, C., Peters, G. J., Ferreira, C. G., Pinedo, H. M., & Giaccone, G. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00425-0 · Cited by 163 · cited 1×
“Cytotoxic anticancer drugs inhibit DNA replication [23] or mitosis [24, 25] resulting in apoptosis in several types of cancers including NSCLC [26], while EGFR-TKI inactivates EGFR signalling in NSCLC cells [27].”
BackgroundDirect Effects of Caffeine and Theophylline on p110δ and Other Phosphoinositide 3-Kinases
Foukas, L. C., Daniele, N., Ktori, C., Anderson, K. E., Jensen, J., & Shepherd, P. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202101200 · Cited by 158 · cited 1×
“It has been reported that Caffeine inhibits ATM-ATR pathway [31] as well as PI3K pathway [34], which are also known as regulators of NKG2D ligands [16, 17].”
BackgroundBoissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J.-M., Rousselot, P., Tamouza, R., Le Bouteiller, P., Mahon, F.-X., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5108 · Cited by 148 · cited 5×
“It is reported that the expression of NKG2D ligands is regulated by DNA stress-induced ATM-ATR signaling [15], while other groups including us reported that oncogenes BCL/ABL and HER3 also regulated the expression of NKG2D ligands in transformed cells via mainly PI3K-AKT pathway [16, 17].”
BackgroundMethodInfluentialNKG2D in NK and T Cell-Mediated Immunity
Ogasawara, K., & Lanier, L. L. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-8786-4 · Cited by 138
Baggstrom, M. Q., Stinchcombe, T. E., Fried, D. B., Poole, C., Hensing, T. A., & Socinski, M. A. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31814617a2 · Cited by 124 · cited 1×
“Cytotoxic anticancer therapy has improved overall survival of patients with non-resectable non-small cell lung cancer (NSCLC) [2].”
BackgroundTsukerman, P., Stern-Ginossar, N., Gur, C., Glasner, A., Nachmani, D., Bauman, Y., Yamin, R., Vitenshtein, A., Stanietsky, N., Bar-Mag, T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2671 · Cited by 120 · cited 1×
“Both substances exert a dissimilar activity on miRNA expression, Gemcitabine, but not Gefitinib decreased both miR10b and miR20a, which were reported as suppressors for expressing NKG2D ligands [43, 44] suggesting that DNA stress may induce NKG2D ligand expression via downregulation of miR10b and miR20a.”
BackgroundS-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells
Hennequin, C., Giocanti, N., & Favaudon, V. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.232 · Cited by 117 · cited 1×
“Cytotoxic anticancer drugs inhibit DNA replication [23] or mitosis [24, 25] resulting in apoptosis in several types of cancers including NSCLC [26], while EGFR-TKI inactivates EGFR signalling in NSCLC cells [27].”
BackgroundYadav, D., Ngolab, J., Lim, R. S.-H., Krishnamurthy, S., & Bui, J. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.39 · Cited by 102
A renaissance for the tumor immunosurveillance hypothesis
Lanier, L. L. (2001) · Nature Medicine · doi:10.1038/nm1101-1178 · Cited by 82 · cited 1×
“NK cells play an important role in immunosurveillance [4].”
BackgroundEissmann, P., Evans, J. H., Mehrabi, M., Rose, E. L., Nedvetzki, S., & Davis, D. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903985 · Cited by 79 · cited 1×
“Both substances exert a dissimilar activity on miRNA expression, Gemcitabine, but not Gefitinib decreased both miR10b and miR20a, which were reported as suppressors for expressing NKG2D ligands [43, 44] suggesting that DNA stress may induce NKG2D ligand expression via downregulation of miR10b and miR20a.”
BackgroundMin, D., Lu, X., Wang, X., Zhang, B., Meng, W., Yu, F., & Hu, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.337 · Cited by 79 · cited 1×
“It has been previously reported that several miRNA suppress the expression of NKG2D ligands [20, 42].”
BackgroundOkita, R., Mougiakakos, D., Ando, T., Mao, Y., Sarhan, D., Wennerberg, E., Seliger, B., Lundqvist, A., Mimura, K., & Kiessling, R. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102237 · Cited by 73 · cited 8×
“Tumor cells were stained with fluorochrome-conjugated antibodies as previously described [17].”
BackgroundMethodResultSelf-citationDecreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB
Tang, K.-F., Ren, H., Cao, J., Zeng, G.-L., Xie, J., Chen, M., Wang, L., & He, C.-X. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801169 · Cited by 73 · cited 1×
“520d could have been described to control the constitutive and/or IFN-γ-induced expression of NKG2D ligands in tumor and virus-infected cells [19–21], and the knock down of the miR biogenesis enzyme DICER upregulated MICA/B expression [22].”
BackgroundEGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells
Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63 · cited 1×
“Although it was previously reported that 10 μM of Gefitinib upregulated NKG2D ligands in lung cancer cell lines [35], Fig 2.”
BackgroundWu, J., Zhang, X., Shi, K., Chen, Y., Ren, Y.-F., Song, Y., Li, G., Xue, Y.-F., Fang, Y., Deng, Z., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt268 · Cited by 44
Morisaki, T., Onishi, H., Koya, N., Kiyota, A., Tanaka, H., Umebayashi, M., Ogino, T., Nagamatsu, I., & Katano, M. (2011) · PubMed · Cited by 44
Uno, K., SETOGUCHI, J., Tanigawa, M., Kishi, A., Ogawa, M., Saotome, H., Fujiwara, H., & Kíshida, T. (1998) · PubMed · Cited by 12
Opposing consequences of signaling through EGF family members
Kiessling, R. W., Okita, R., Mougiakakos, D., Mao, Y., Sarhan, D., Wennerberg, E., Seliger, B., Lundqvist, A., Mimura, K., & Kono, K. (2012) · OncoImmunology · doi:10.4161/onci.20685 · Cited by 2 · cited 2×
“A direct control of MICA by the BCR/ABL oncogene in chronic myelogenous leukemia had been described [16], while the HER2-HER3 signalling was involved in the regulation of MICA/B expression in breast cancer cell lines [17, 18].”
BackgroundSelf-citation
Cited by
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Soo, R. A., Lim, S. M., Syn, N. L., Teng, R., Soong, R., Mok, T. S. K., & Cho, B. C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 153
Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1986-y · Cited by 159
Self-citationLizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
Metadata
- Authors
- Okita, R., Wolf, D., Yasuda, K., Maeda, A., Yukawa, T., Saisho, S., Shimizu, K., Yamaguchi, Y., Oka, M., Nakayama, E., Lundqvist, A., Kiessling, R., Seliger, B., & Nakata, M.
- Affiliations
- Kawasaki Medical School (JP)
- Kawasaki University of Medical Welfare (JP)
- Karolinska Institutet (SE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Okita, Riki
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-06
- Volume
- 10
- Issue
- 10
- Pages
- e0139809
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4595469
- OpenAlex
- W2175265591
- Cited by
- 39
- References
- 45
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 7 · 2016: 3
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (GRK 1591)
- Cancerfonden
- Kommunfullmäktige, Stockholms Stad
- Knut och Alice Wallenbergs Stiftelse
- Kawasaki Medical School
- Medical Research Council
- Japan Society for the Promotion of Science (25462189, 24890284, 121103, 15K09235)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- gemcitabine, gefitinib, NKG2D ligands, NK cell cytotoxicity, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, PI3K signaling, MICA/B, miR-20a, tumor immunogenicity, drug resistance
- MeSH terms
- Gefitinib, Gemcitabine, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Deoxycytidine, Humans, Killer Cells, Natural, Lung Neoplasms, Quinazolines, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, NK Cell Lectin-Like Receptor Subfamily K, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.